摘要Neurodegenerative disorders represent a pervasive global health challenge,yet therapeutic options remain conspicuously limited.These disorders are inherently dynamic processes within the central nervous system,unfolding across distinct sub-stages:initial structural neuronal alterations(sub-stage 1),functional impairment(sub-stage 2),and culminating in neuronal death(sub-stage 3).Previous studies have revealed shared pathological features between amyotrophic lateral sclerosis(ALS)and Parkinson's disease(PD)(van Rheenen et al.,2021;Mantle and Hargreaves,2022)including common genetic risk factors identified through genome-wide association studies(van Rheenen et al.,2021).Both disorders manifest similar neurodegenerative mechanisms,such as oligomer formation,aberrant protein accumulation,and protein misfolding-specifically,superoxide dismutase 1 in ALS and α-synuclein in PD.Mitochondrial dysfunction further serves as a common denominator in the pathogenesis of ALS and PD(Mantle and Hargreaves,2022).